Portfolio
Actelion Pharmaceuticals Ltd is a biopharmaceutical company. Its lead product Tracleer® is an orally available dual endothelin receptor antagonist.
Tracleer® was licensed from Hoffmann-La Roche and further developed and commercialised by Actelion Pharmaceuticals Ltd as a therapy for pulmonary arterial hypertension. The company built commercial operations to market the product through its own subsidiaries in key markets worldwide.
In 2000 Actelion Pharmaceuticals Ltd successfully completed an Initial Public Offering on the Swiss Stock Exchange (SIX:ATLN).
Status: Realised
Investment
NeoMed identified Actelion Pharmaceuticals Ltd as an attractive investment opportunity in 1998 and had early access to the opportunity through personal contacts and network in Switzerland.
NeoMed participated in the Series A financing and provided occasional strategic advice to the management.
NeoMed sold its shares on the Swiss Stock Exchange in 2001 and 2002.